Following this multi-tumor screening, the large NSCLC, ovarian cancer, and pancreatic adenocarcinoma cohorts were used to further explore patterns of CD40 expression, as well as potential prognostic value and possible correlations with clinicopathologic features. This evidence concerns the gene CD40 and non-small cell lung carcinoma.